Edition:
United States

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

12.65USD
26 May 2017
Change (% chg)

$-0.25 (-1.94%)
Prev Close
$12.90
Open
$12.85
Day's High
$12.85
Day's Low
$12.60
Volume
21,956
Avg. Vol
50,893
52-wk High
$13.82
52-wk Low
$7.33

ZGNX.OQ

Chart for ZGNX.OQ

About

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008,... (more)

Overall

Beta: 1.92
Market Cap(Mil.): $313.89
Shares Outstanding(Mil.): 24.81
Dividend: --
Yield (%): --

Financials

  ZGNX.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -3.21 -- --
ROI: -34.84 -8.48 -5.42
ROE: -57.89 -11.31 -4.68

BRIEF-Zogenix Q1 loss per share $0.86

* Zogenix provides corporate update and reports first quarter 2017 financial results

May 04 2017

BRIEF-Zogenix completes enrollment in first ZX008 Phase 3 clinical trial in Dravet syndrome

* Zogenix completes enrollment in first zx008 phase 3 clinical trial in dravet syndrome

Apr 27 2017

BRIEF-Zogenix Q4 loss per share $0.95

* Zogenix provides corporate update and reports fourth quarter and full-year 2016 financial results

Mar 09 2017

BRIEF-Zogenix receives orphan drug designation in the EU for zx008 in lennox gastaut syndrome

* Zogenix Inc- receives orphan drug designation in european union for zx008 in lennox gastaut syndrome

Mar 01 2017

BRIEF-Zogenix Inc says European Commission designated ZX008 as an orphan medicinal product

* Zogenix Inc - on March 1, 2017, co announced that european commission has designated zx008 (fenfluramine) as an orphan medicinal product-sec filing

Mar 01 2017

BRIEF-Perceptive Advisors LLC reports 5.46 pct passive stake in Zogenix

* Perceptive Advisors LLC reports 5.46 percent passive stake in Zogenix Inc as of Feb 15 - sec filing Source text : http://bit.ly/2loI5VN Further company coverage:

Feb 22 2017

BRIEF-Zogenix announces initiation of clinical efficacy portion of study

* Zogenix announces initiation of clinical efficacy portion of study 1504 for ZX008 in dravet syndrome Source text for Eikon: Further company coverage:

Feb 13 2017

More From Around the Web

Earnings vs. Estimates